Global Orthopedic Regenerative Surgical Products Market Size, Share & Industry Trends Analysis Report By End-Use (Hospitals, Ambulatory Surgical Centers and Others), By Application, By Product, By Regional Outlook and Forecast, 2023 - 2030

Global Orthopedic Regenerative Surgical Products Market Size, Share & Industry Trends Analysis Report By End-Use (Hospitals, Ambulatory Surgical Centers and Others), By Application, By Product, By Regional Outlook and Forecast, 2023 - 2030

The Global Orthopedic Regenerative Surgical Products Market size is expected to reach $5.4 billion by 2030, rising at a market growth of 4.2% CAGR during the forecast period.

Over the past ten years, interest in orthobiologics, which includes amniotic materials, has grown for the treatment of numerous orthopedic disorders, including osteoarthritis. Consequently, the Amniotic Products segment will capture around 3/4th share in the market by 2030. One subtype of orthobiologics that is being researched as a potential therapeutic option involves enhancing joint inflammation and healing with amniotic-derived materials, such as amniotic membranes as well as amniotic fluid products. In recent years, research into amniotic-derived products for orthopedic tissue regeneration, including ligament and tendon healing, treatment of plantar fasciitis, spinal pathologies, cartilage restoration, and osteoarthritis, has increased. Some of the factors impacting the market are the increasing number of orthopedic conditions, rising R&D investments propelling technological improvements, and low reimbursement rates and onerous regulatory requirements.

Orthopedic regenerative surgical solutions are in high demand due to the rising prevalence of musculoskeletal problems and orthopedic injuries like tendinitis (tendonitis), osteoarthritis, and ligament injuries. One of the injuries widely researched in orthopedic treatment and research is a ligament damage known as an anterior cruciate ligament (ACL) injury. In professional football, these accidents are becoming more frequent. Osteoarthritis (OA) is the most prevalent type of arthritis, while there are thought to be more than 100 different forms. The high frequency of arthritis results in significant personal and societal consequences. Furthermore, Products for orthopedic regenerative surgery are anticipated to profit from technological developments by expanding R&D research and utilizing cutting-edge technologies, including viscosupplements, stem cells, and platelet rich plasma (PRP) therapies. In a study published in the International Journal of Complementary and Alternative Medicine, many survey participants supported using regenerative medicine therapies to address musculoskeletal problems. Therefore, the market will grow due to the increase in the number of orthopedic conditions and the technological developments in regenerative medicines.

However, the Centers for Medicare and Medicaid Services (CMS) establish payment schedules and decide which operations and technologies are worth paying for. Recent CMS reimbursement rate cuts could cost hospitals, and surgery centers billions of dollars. The Comprehensive Care for Joint Replacement model is a new value-based payment scheme that CMS introduced in 2016. Healthcare professionals and patients may be reluctant to use these therapies if payment policies for orthopedic regenerative surgical products are insufficient or unclear. Financial obstacles resulting from reimbursement issues may restrict patients' access to these treatments. Thus, the difficulties in the provision and accessibility of reimbursement policies may hamper the market's growth.

Additionally, as a result of decreased sales and demand, interruptions in clinical research, and the postponement of elective treatments, the COVID-19 pandemic had a negative influence on the market. As a result of disruptions in the supply chain, travel restrictions, closures of businesses, illness or quarantine among employees, and policies for social distance, organizations experienced additional operational obstacles. To reduce the risk of cross-contamination and increase the capacity to treat patients infected with the coronavirus, a significant number of medical facilities around the world suspended or postponed scheduled elective surgical procedures. However, in the coming years, the market is expected to grow owing to the resumption of elective operations.

End-use Outlook

Based on end-use, the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment procured the highest revenue share in the market in 2022. The main source of revenue for the healthcare business and a crucial component that fosters innovation and research are hospitals. The overwhelming presence of the hospital market can be traced to the fact that most orthopedic procedures occur in hospitals.

Application Outlook

By application, the market is divided into orthopedic pain management, trauma repair, cartilage & tendon repair, joint reconstruction, and others. The cartilage and tendon repair segment garnered a remarkable growth rate in the market in 2022. Numerous variables, including the expanding number of geriatric patients, trauma cases, and sports medical applications, are responsible for the expansion of the segment. The ability of cartilage to heal itself is low. Due to chondral lesions or painful cartilage, surgery may be required for people with joint dysfunction (e.g., knee, ankle, hip, or elbow). Successful cartilage surgery lessens discomfort and improves functionality.

Product Outlook

Based on product, the market is characterized into allografts, synthetic, cell-based, and viscosupplements. The viscosupplements segment garnered the highest revenue share in the market in 2022. The increase in osteoarthritis cases and knee pain has been attributed to the growth of the segment. Knee osteoarthritis is exacerbated by factors including obesity, external injuries, excessive activity, hereditary susceptibility, and aging, which is why there is such a high demand for the product.

Allografts Outlook

The allografts segment is further classified into amniotic products and others. The others segment recorded a significant revenue share in the market in 2022. The others segment can include bone allografts, tendon allografts, cartilage allografts, meniscus allografts, skin allografts, soft tissue allografts, and demineralized bone matrix (DBM). Depending on the patient's condition, the surgery, and the surgeon's discretion, a particular allograft type may be employed.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the market in 2022. The dominance of this regional market can be linked to several elements, including the existence of important players, technologically cutting-edge healthcare systems in Canada and the United States, and the rising senior population. For example, as of July 2022, Canada had 7.3 million people who are 65 or older, with a median age of 41 years, according to figures from Statistics Canada.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include MiMedx Group, Inc., Vericel Corporation, Baxter International, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Smith & Nephew, Arthrex, Inc., BioTissue Holdings, Inc., VSY Biotechnology GmbH and Aptissen S.A.

Scope of the Study

Market Segments covered in the Report:

By End-use

• Hospitals
• Ambulatory Surgical Centers
• Others

By Application

• Joint Reconstruction
• Cartilage & Tendon Repair
• Trauma Repair
• Orthopedic Pain Management
• Others

By Product

• Viscosupplements
• Allografts
• Amniotic Products
• Others
• Synthetic
• Cell-based

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled

• MiMedx Group, Inc.
• Vericel Corporation
• Baxter International, Inc.
• Zimmer Biomet Holdings, Inc.
• Stryker Corporation
• Smith & Nephew
• Arthrex, Inc.
• BioTissue Holdings, Inc.
• VSY Biotechnology GmbH
• Aptissen S.A.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free